Smoking Cessation

Achieve Life Sciences announced positive top-line results of the RAUORA trial demonstrating that cytisinicline was noninferior to varenicline for smoking cessation.

Lifestyle approaches, including physical activity and smoking cessation, should complement medical therapy in patients with rheumatic and musculoskeletal diseases, according to data presented at the EULAR 2020 E-Congress.

People who smoke occasionally — even just a few times a month — still have a mortality risk significantly higher than never smokers, suggesting that complete cessation is needed to lower risks, according to a study published in JAMA Network Open.

People who quit smoking prior to a lung cancer diagnosis demonstrated considerably reduced risk for death due to all causes compared with those who continued to smoke, according to study results scheduled for presentation during the ASCO20 Virtual Scientific Program.

The U.S. Preventive Services Task Force recommended that primary care clinicians provide interventions to prevent school-aged children and adolescents from using tobacco, such as offering education or brief counseling. However, the task force said there is insufficient evidence to support primary care interventions for the cessation of tobacco use among children who already smoke.

Individuals who began smoking at a younger age were more likely to be daily smokers as adults and less likely to have quit smoking by their 40s, according to findings from the International Childhood Cardiovascular Cohort published in the Journal of the American Heart Association.

In the randomized E3 trial, nicotine e-cigarettes combined with individual counseling was more effective for smoking cessation at 12 weeks than non-nicotine e-cigarettes with counseling or counseling alone.

Cancer death rates declined between 2001 and 2017 in the United States for all cancer sites combined, according to the Annual Report to the Nation on the Status of Cancer published in Cancer.

Combining reduced-harm nicotine products can lead to improvement in smoking cessation without short-term harm, according to a study published in The Lancet Respiratory Medicine.

Varenicline did not appear associated with increased risk for cardiovascular or neuropsychiatric hospitalization compared with nicotine replacement therapies, according to a retrospective new-user cohort study published in Addiction.